Torii Pharmaceutical Co., Ltd.

4551

JP3635800000

TORII PHARMACEUTICAL CO., LTD. is mainly engaged in the manufacture and sale of pharmaceutical products. The Companyâs main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Companyâs main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Sector

Pharmaceuticals

Calendar

2024-06-26 - Ex-dividend day for dividende intermédiaire

More about the company

Income Statement Evolution

More financial data

Ratings for Torii Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TORII PHARMACEUTICAL CO., LTD.	+8.44%	688M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
3,855 ^JPY	+1.72%		+4.47%	+8.44%

Feb. 13	LIM Advisors Partially Withdraws Shareholder Proposal	CI
Feb. 09	Torii Pharmaceuticals Opposes Shareholder Proposal	CI

LIM Advisors Partially Withdraws Shareholder Proposal	Feb. 12	CI
Torii Pharmaceuticals Opposes Shareholder Proposal	Feb. 08	CI
Verrica Pharmaceuticals' Partner Reports Positive Data From Phase 3 Trial of Skin Infection Treatment	Dec. 15	MT
Torii Pharmaceutical Co., Ltd. Announces Positive Top-Line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan	Dec. 15	CI
ALK Abello Adds Grass Pollen Allergy Drug to Torii License Deal in Japan	Dec. 12	MT
ALK-Abelló A/S Expands Partnership with Torii Pharmaceutical Co., Ltd. in Japan	Dec. 12	CI
BioCryst Amends Deal With Torii Pharmaceutical for Orladeyo's Commercialization in Japan; Shares Rise	Nov. 30	MT
Torii Pharmaceutical Announces Voting Results	23-03-30	CI
LIM Advisors Submits Shareholder Proposal to Torii Pharmaceutials	23-02-10	CI
Japan Tobacco urged to sell drug unit by activist shareholder LIM	23-01-20	RE
Verrica Pharmaceuticals Receives $8 Million Milestone Payment From Torii Pharmaceutical After Phase 3 Viral Skin Disease Trial Gets Underway	22-08-01	MT
Torii Pharmaceutical Co., Ltd. Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum	22-08-01	CI
Torii Pharmaceutical Announces the Voting Results	22-03-31	CI
Effissimo Capital Management Submits Shareholder Proposal to Torii Pharmaceutical	21-08-06	CI
Torii Pharmaceutical Co., Ltd. Plans to Launch of CORECTIM Ointment 0.25% in Japan	21-05-26	CI
Sector Update: Health Care	21-04-15	MT
BioCryst Pharmaceuticals' : Orladeyo Receives Approval for Japanese NHI Price Listing	21-04-14	MT
Akebia Therapeutics : Obtains Approval For Additional Indication of Riona Tablets in Japan	21-03-24	MT
Japan Tobacco : Torii Pharmaceutical's Atopic Dermatitis Ointment Receives Manufacturing, Marketing Approval; Shares Fall 3%	21-03-24	MT
Verrica Pharmaceuticals : Torii Strike Exclusive Licensing Deal To Develop, Commercialize VP-102 For Molluscum, Common Warts in Japan	21-03-17	MT
Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan	21-03-17	CI
Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. Receives Manufacturing and Marketing Approval of Enaroy Tablets 2 Mg4 Mg	20-09-25	CI
Iwaki Seiyaku Co., Ltd. completed the acquisition of Sakura Plant from Torii Pharmaceutical Co., Ltd..	20-06-30	CI
Torii and ASKA Enter into Co-Promotion Agreement Concerning Additional Indication of Iron Deficiency Anemia for Riona	20-06-01	CI
Japan Tobacco Inc. Files New Drug Application of Jte-052 Ointment, Jak Inhibitor, for the Treatment of Pediatric Atopic Dermatitis in Japan	20-05-29	CI

Torii Pharmaceutical Co., Ltd.

Equities